Is a Bioscience Career Worth the Aggravation?

While this isn’t a new topic, I wanted to raise the question again because I recently received a message  from a reader that greatly troubled me. The person who posted the comment has a PhD degree in biomedical engineering and is extremely angry with the existing system because of the lack of employment opportunities in her field. Put simply, she is so frustrated with the system that she no longer believes that it is ethical to advise young people to pursue careers in the life sciences. I know that she isn’t alone and that many of you share her anger and frustration with the lies (as she put it) about employment opportunities for life sciences PhD candidates and postdoctoral fellows

From time to time, I am invited by graduate students and postdoctoral fellows to talk about alternative careers in the life sciences. I try to remain upbeat and positive during my presentation but generally I can’t control myself by the Q&A session. Invariably, I rant and rave about how dysfunctional academia has become. Interestingly, I recently was uninvited by my former graduate department where I was slated to present a seminar on alternate career choices for life scientists. As the tenured faculty member (you know how I feel about tenure) who would have sponsored my visit told me “the seminars that we offer our students are scientific in nature and much different than many of the topics that I discuss on my very interesting blog.” Consequently, he informed me that I was no longer invited to give my talk (I was previously invited by the Department Chair who happened to be a former colleague of mine who decided to move to another institution before my visit). In an e-mail response to his un-invitation, I told him that I wanted to visit the Department and give the talk because I believe that my graduate education is what enabled me to maneuver the minefield that ultimately became my career path. Also, I told him that I wanted to share my insights and career experiences with current graduate students and postdoctoral fellows because I thought that many may benefit from them. Not surprisingly, I never heard back from him. 

The point that I am trying to make is that my message about alternative careers for PhD students is diametrically opposed to the mission of most PhD programs; which is to prepare 100% of their students for academic careers. Unfortunately, as I have stated many times in the past, only about 10% of those who receive life sciences PhD degrees land academic appointments. What are the remaining 90% of the folks who toiled long and hard for their PhD degrees suppose to do with their lives? In the past, as many as 50% or more of these students were able to garner jobs as research scientists at biotechnology and pharmaceutical companies or with government agencies like the CDC, FDA, EPA and others. Unfortunately, the pharmaceutical industry has laid off over 200,000 employees in the past 3 years, funding for biotech companies has hit an all time low and we are experiencing the worst recession in almost 70 years which is causing government agencies to stop hiring! This begs the question: what are graduate students pursuing PhD degrees and postdoctoral fellows suppose to do to put food on the table to feed their families and themselves? 

While I don’t have an easy answer to that question, I can tell you that getting angry and frustrated or dropping out of the system isn’t going to change anything. I will also tell you that the system isn’t going to change by itself! To that end, it may make sense for all of you angry and frustrated graduate students and postdoctoral fellows to band together and tell your advisors and mentors that “you are mad as hell and not going to take it anymore.” To show them that you are serious, I highly recommend that your offer them a plan to address your concerns about finding gainful employment (not decade long postdoctoral fellowships) following completion of your PhD degrees. For example, you may suggest that they add alternate career certificate and degree programs to their existing curricula. Or, if new programs are too costly, suggest that they offer courses that showcase alternate career options like entrepreneurship, science writing or medical communications. Finally, at the very list, insist that they work with local companies and organization to create sponsored internship opportunities and get them to commit to supporting annual career development symposia or job fairs for graduate students and postdocs.

For the past decade or more, I have struggled to convince many of my academic colleagues to consider any and all of the above suggestions. Unfortunately, my pleas for creation of new courses and programs have fallen upon deaf ears! Given my current lack of success, I suspect that it is going to take more than one person (me) to induce the academic establishment to consider systemic change. That said anybody who may be interested in joining the “cause” to improve employment opportunities for PhD life scientists, please feel free to contact me!

Until next time...

Good Luck and Good Organizing!!!!!

 

Is Biotechnology in Your Future?

Despite its humble beginnings in the late 1970s, the biotechnology industry has transformed itself into one of the most vibrant sectors of the American economy. Pharmaceutical companies, once the bell weather of the life sciences industry, have finally conceded that biotechnology and not small molecules are the industry’s future!

While growth of the biotechnology industry has slowed somewhat in the past couple of years—mainly because of the recession—it still represents a viable career option for students interested in the biological sciences. Contrary to popular belief, a PhD degree is no longer required to gain employment in the biotechnology industry. The PhD degree option is slowly being replaced by biotechnology masters and undergraduate degrees and certificate programs readily available at many two year colleges. Put simply, there is a decreasing demand for PhDs at many life sciences companies—mostly because of technological advances and a growing reliance on outsourcing to carry out drug discovery and development. However, the demand for non-PhD employees with solid biotechnology backgrounds particularly in the areas of regulatory affairs, licensing, business development, medical communications, health informatics and biomanufacturing is rising.

For many students (especially high school and undergraduates), the plethora of biotechnology degree and certificate programs can be overwhelming. With this in mind, I came across a cool website called Biotechnology Degree Guide which helps students decide which program is right for them. The site is run by Webster Jorgensen who sent me the following information about the site.

“Biotechnology Degree Guide was developed to be a complete and comprehensive guide for finding colleges, universities and technical schools offering biotech and related programs. The site also features a rating system that allows registered users to rate various biotechnology programs. This feature was added to help separate the great programs from the not-sop-great ones. In the future, we plan to start highlighting "Hidden Gem" programs section that helps schools with lower profiles and great programs receive more exposure. The sites members section is open to prospective students, students, professionals, teachers and biotech hobbyists.  A social media component is planned for the future.”

While the Biotechnology Degree Guide may not answer all of your questions, it certainly is a good place to start when considering a career in biotechnology!

Until next time...

Good Luck and Good Job Hunting!!!!!!!!!!

 

SocialTwist Tell-a-Friend

Can Scientists Be Effective CEOs?

Over the past 30 years or so, the vast majority of chief executives in the drug business have made their way to the top via the sales and marketing departments. Few senior executives have toiled in a research laboratory or for that matter, know the difference between NMR and protein purification. However, things may be changing in the industry. A quick perusal of the CEOs of the top 20 pharmaceutical and biotechnology companies (see below) reveals that 11 of 20 have degrees in engineering (4), medicine (2) and science (5). The remaining 9 have degrees in business and finance (3), sales and marketing (4) or law (2). Several of the scientists (2), engineers (3) and one physician also earned MBA degrees.

 

Conventional wisdom suggests that scientists usually do not make good CEOs (they are not formally trained in business). However, doesn’t the lack of scientific sensibility put non-scientist CEOs at a disadvantage when it comes to making strategic and operational decisions about R &D?  One would think so….!!!!

 

A careful examination of my top 20 list suggests that some of the most successful companies are run by scientist CEOs, e.g. Genentech, Gilead, Novartis and Lilly. Expect to see more scientist CEOs at large biotechnology and pharmaceutical companies in the future–R&D have become way too complex for non-scientist to truly understand its nuances and potential pitfalls. Plus, we scientists know that obtaining a MBA degree is a “piece of cake” as compared with the PhD degree! Hmmm, I wonder what business people think about PhDs?

Company

Name

Background

2006 Total Compensation

Abbott

Miles White

Mechanical Engineering and Business (MBA)

$26,915,358 

Amgen

Kevin Sharer

Aeronautical Engineering and Business (MBA)

$34,390,000

AstraZeneca

David Brennan

Sales and Marketing

$4,226,000 

Biogen/IDEC

James Mullen

Chemical Engineering

$1,450,000

Bristol-Myers Squibb

Jim Cornelius

Business (MBA) and Finance

$1,472,879

Eli Lilly

John Lechleiter

Chemistry (PhD)

Not available (newly appointed)

Genentech

Arthur D. Levinson

Molecular Biology (PhD)

$17,124,025 

Genzyme

Henri A. Termeer

Finance and Business (MBA)

$36,380,000

Gilead

John C. Martinis

Organic Chemistry (PhD), Chemical Engineering and Business (MBA)

$22,860,000

GlaxoSmithKline

JP Garnier

Pharmacology (PhD) and Business (MBA)

$5,413,000 

Johnson & Johnson

William C. Weldon

Sales and Marketing

$28,557,749 

MedImmune

David Mott

Banking and Investment

$11,411,897

Merck

Richard T. Clark

Business and Marketing (MBA)

$10,236,740

Millennium

Deborah Dunsire

Physician (MD)

$3,874,464

Novartis

Daniel Vasella

Physician (MD) and Business (MBA)

3,199,505 CHF

Pfizer

Jeffery Kindler

Lawyer

$9,799,233 

Roche

Severin Schwan

Lawyer and Finance

Not available (newly appointed)

Sanofi Aventis

Gerard Le Fur,

Pharmaceutical Sciences (PhD)

Not available (newly appointed)

Schering Plough

Fred Hassan

Chemical Engineering and Business (MBA)

$5,790,000

Wyeth

Bernard Poussot

Business and Finance

Not available (newly appointed)

Until next time….

Good Luck and Good Job Hunting!!!!!!!!